Nyxoah SA (NASDAQ:NYXH – Get Free Report) saw a significant increase in short interest in October. As of October 30th, there was short interest totaling 331,332 shares, an increase of 55.1% from the October 15th total of 213,619 shares. Approximately 0.9% of the company’s shares are short sold. Based on an average trading volume of 337,038 shares, the short-interest ratio is currently 1.0 days.
Nyxoah Price Performance
Nyxoah stock opened at $0.90 on Wednesday. The firm has a 50-day moving average price of $1.17 and a 200-day moving average price of $2.28. The firm has a market capitalization of $34.88 million, a PE ratio of -0.45 and a beta of 1.80. The company has a current ratio of 2.19, a quick ratio of 2.08 and a debt-to-equity ratio of 0.53. Nyxoah has a 12-month low of $0.80 and a 12-month high of $5.39.
Nyxoah (NASDAQ:NYXH – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. The firm had revenue of $10.39 million during the quarter, compared to analysts’ expectations of $11.45 million. Nyxoah had a negative net margin of 313.03% and a negative return on equity of 153.98%. As a group, equities research analysts forecast that Nyxoah will post -1.40 EPS for the current year.
Institutional Investors Weigh In On Nyxoah
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on NYXH shares. Raymond James Financial set a $3.00 price objective on Nyxoah in a research report on Tuesday, October 27th. Piper Sandler reaffirmed an “overweight” rating and issued a $6.00 price objective (down from $7.00) on shares of Nyxoah in a research note on Thursday, August 6th. Wall Street Zen upgraded Nyxoah from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of Nyxoah in a research report on Tuesday. Finally, Cantor Fitzgerald cut their target price on Nyxoah to $3.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 27th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $3.55.
View Our Latest Stock Report on NYXH
About Nyxoah
Nyxoah is a medical technology company focused on treatments for obstructive sleep apnea (OSA), a condition in which breathing repeatedly stops or becomes shallow during sleep. The company develops implantable neurostimulation systems for patients who cannot use or do not benefit from conventional therapies such as continuous positive airway pressure. Its lead product, the Genio system, stimulates the hypoglossal nerve to help keep the tongue from obstructing the airway during sleep. The system uses an implanted stimulator and an external wearable component, and is designed to stimulate both sides of the nerve.
See Also
- Five stocks we like better than Nyxoah
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.
